Navigation Links
STAAR Surgical Completes Common Stock Offering
Date:6/17/2009

MONROVIA, Calif., June 17 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a developer, manufacturer and marketer of implantable lenses and related ophthalmic products, today announced the completion of a registered direct offering of 4,255,319 shares of its common stock, at a price of $1.88 per share, which was the closing market price on June 16, 2009. The net proceeds will be approximately $8.0 million because the Company did not use an underwriter for this transaction. This transaction was funded by unanimous participation among STAAR's largest shareholders, demonstrating continued investor support for the Company and its technology.

STAAR intends to use the proceeds to fund a deposit with the court to secure a stay of enforcement of the judgment pending STAAR's appeal in the Parallax Medical Systems, Inc. litigation. The current temporary stay in the case expires on June 22, 2009. All shares of common stock offered by STAAR were sold pursuant to a shelf registration statement that was declared effective by the U.S. Securities and Exchange Commission on June 12, 2009. No other securities were issued in connection with this offering. The offering is expected to close on or about June 17, 2009.

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 50 countries. Collamer(R) is the brand
'/>"/>

SOURCE STAAR Surgical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
2. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
3. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
4. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
5. STAAR Surgical Reports 33% Third Quarter Revenue Growth
6. STAAR Surgical to Present at the Noble Financial Equity Conference
7. STAAR Surgicals Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification
8. STAAR Surgicals LASIK Alternative Expands U.S. Market Gains
9. STAAR Surgical Reports Solid First Quarter Progress
10. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
11. STAAR Surgical Plans Major Presence at ASCRS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Global ... organization, and Bodybuilding.com, the largest online retailer of health ... a new reality-based sports show, Warrior Island. “We ... on; YouTube, Facebook & Twitter, with our unique social ... Island maroons these elite fighters on an island in ...
(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
(Date:5/21/2013)... or the removal of the adenoids and tonsils, is ... often as a treatment for children with obstructive sleep ... child,s attention and executive functioning, behavior, sleep apnea symptoms, ... until now. A study led by Susan Redline, ... and Cardiovascular Medicine and Associate Clinic Director of the ...
(Date:5/21/2013)... Go Classy Tours, the oldest and ... redesigned their website featuring N Resort in Jamaica ... bars and dining. The website, which has always featured ... guest reviews, will now have a broader range of ... on culinary local recipes, flora and fauna, featured pictures ...
(Date:5/21/2013)... 2013 The American Diabetes Association ( ... the United States of America are affected with peripheral ... great risk of developing peripheral neuropathy which unfortunately makes ... ADA further goes on saying that the disease usually ... 2 million new cases are diagnosed every year in ...
Breaking Medicine News(10 mins):Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
... that points to a new strategy for preventing or possibly ... and tissue damage researchers at the University of ... molecule called Epac (Exchange protein activated by cAMP1), plays a ... The research will be published in the online edition ...
... Specialized Bicycles; Goodby, Silverstein & Partners;, and Google Challenged Participants ... ... ROCK, Ark., April 22 The William J. Clinton,Presidential Center and ... April 26., This year,s festival will host "The Aquaduct: Mobile ...
... of the Cycling Event for the,5th Consecutive Year, ... Store, America,s leading supplier of power wheelchairs and,scooters, raised ... Multiple,Sclerosis Society by participating in the MS150 bike ride., ... a Platinum Sponsor of,the two-day cycling journey from Houston ...
... Abbott (NYSE:,ABT) will present at the Morgan ... 2008. Thomas C. Freyman, executive vice,president, finance and ... company at 7:30 a.m. Central time., A ... accessible through,Abbott,s Investor Relations Web site at ...
... PA, NC, SC, GA and,FL, WEST POINT, ... not-for-profit senior living,organization, announced today that it has ... Cove, a continuing care retirement community (CCRC),in Huntsville, ... May 30., Following the closing of this ...
... in radiology and medical image and information management,solutions, today announced it will ... before the market opens on,Thursday, May 1, 2008., ... -- Thursday, May 1, 2008 ... 7:30 a.m. ...
Cached Medicine News:Health News:Scientists identify novel way to prevent cardiac fibrosis 2Health News:Clinton Center's Earth Day to Feature 'Innovate or Die Contest' Winner 2Health News:The SCOOTER Store and Their Employees Contribute $43,000 in MS150 Bike Ride to Help Texans With Multiple Sclerosis 2Health News:PA-Based ACTS Retirement-Life Communities Announces Agreement to Acquire Carlton Cove in Huntsville, Alabama 2Health News:AMICAS Schedules First Quarter 2008 Earnings Call 2
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: VASO) ... design, manufacture and sale of medical devices and in the ... Jun Ma , President and CEO of ... MicroCap Conference on Thursday, May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Coherence Tomography (OCT) http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ...   BCC,s aim ... synopsis of the current and future characteristics ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... , Beverage Can Stay-Tabs Pose Swallowing Risk ... reports that beverage can stay-tabs pose a potential ingestion risk. ... after safety concerns about pull-tabs. The new study found 19 ... teenagers. Further, the study found that most ingested stay-tabs are ...
... , CHICAGO, Nov. 30 A large ... receive unindicated and unnecessary additional image acquisition resulting in ... today at the annual meeting of the Radiological Society ... of all physicians who work with ionizing radiation to ...
Cached Medicine Technology:Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 2Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 3Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 2Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 3
... is the cycler that revolutionized thermal cycling. ... consistent results, experiment-to-experiment and block-to-block. This rugged ... it's a platform for new features and ... thermal cycler chassis, does not include the ...
... The Gene Cycler unit is an inexpensive personal ... for the PCR process. Lightweight, with a small ... almost anywhere, including the researcher's desk. , The ... researchers who do not have access to a ...
Contains: Card, cabling and instructions to remotely access a RoboCycler® instrument from a PC or Macintosh® computer...
... Ideal for day-to-day temperature ... of 0.1C ,30% reduction ... Peltier or coolant-based cyclers ... temperature ramping ,Options for ...
Medicine Products: